Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients ≥80 years treated with high-dose methotrexate-based chemotherapy

References

• Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary Central nervous system lymphoma over the past 4 decades. Neurooncology. 2018;20(5):687–694.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Müller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20(2):319–325.
   PubMed Web of Science ®Google Scholar
• Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–3979.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–1047.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (alliance 50202). J Clin Oncol. 2013;31(25):3061–3068.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846–852.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–2085.
   PubMed Web of Science ®Google Scholar
• van der Meulen M, Bromberg JEC, Nijland M, et al. Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in The Netherlands. Haematologica. 2021;106(2):597–600.
   PubMed Web of Science ®Google Scholar
• Panageas KS, Elkin EB, Ben-Porat L, et al. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. 2007;110(6):1338–1344.
   PubMed Web of Science ®Google Scholar
• Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at memorial Sloan-Kettering cancer center. Neuro Oncol. 2012;14(10):1304–1311. Internet
   PubMed Web of Science ®Google Scholar
• Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era. Neurology [Internet]. 2020;94(10):e1027 LP–e1039.
   Web of Science ®Google Scholar
• Maarek A, Maucort-Boulch D, Houillier C, et al. P14.45 primary diffuse large B-cell CNS lymphoma over 80 years: an analysis of 110 patients from the French oculo-cerebral lymphoma (LOC) network. Neurooncology [Internet. 2019;21(Supplement_3):iii77–iii77.
   Google Scholar
• Dolgin M, et al. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th Edition, United States of America: Lippincott Williams and Wilkins, 1994.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Seidel S, Margold M, Kowalski T, et al. Patients with primary central nervous system lymphoma not eligible for clinical trials: prognostic factors, treatment and outcome. Cancers. 2021;13(12):2934.
   PubMed Web of Science ®Google Scholar
• Seidel S, Korfel A, Kowalski T, et al. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis. Neurological Research and Practice, 2019;2:1–9.
   Google Scholar
• Seidel S, Kowalski T, Margold M, et al. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series. Ther Adv Neurol Disord. 2020;13:1756286420951087.
   Web of Science ®Google Scholar
• Andersen KM, Bates BA, Rashidi ES, National COVID Cohort Collaborative Consortium, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the national COVID cohort collaborative. Lancet Rheumatol. 2022;4(1):e33–e41.
   PubMedGoogle Scholar
• Abrey LE, Batchelor TT, Ferreri AJM, International Primary CNS Lymphoma Collaborative Group, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043.
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–186.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Bessell E, Bromberg J, European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322-32–e332.
   PubMed Web of Science ®Google Scholar
• Anton S, Margold M, Kowalski T, et al. Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: a single-institution experience on 1247 installations in 94 consecutive patients. Hematol Oncol. 2021;39(2):176–184.
   PubMed Web of Science ®Google Scholar
• Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncology [Internet]. 2010;11(9):871–879. Available from
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489–4495.
   PubMed Web of Science ®Google Scholar
• Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary Central nervous system lymphoma. Ann Neurol. 2010;67(2):182–189.
   PubMed Web of Science ®Google Scholar
• Seidel S, Pels H, Schlömer S, et al. Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. Neurology [Internet]. 2020;95(23):e3138–e3144.
   PubMed Web of Science ®Google Scholar
• Unger JM, Vaidya R, Albain KS, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474–1486.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay J-Y, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol. 2003;21(2):266–272.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol. 2006;24(36):5711–5715.
   PubMed Web of Science ®Google Scholar